WO2005003101A3 - Pyrazine and pyridine derivatives as rho kinase inhibitors - Google Patents

Pyrazine and pyridine derivatives as rho kinase inhibitors Download PDF

Info

Publication number
WO2005003101A3
WO2005003101A3 PCT/GB2004/002849 GB2004002849W WO2005003101A3 WO 2005003101 A3 WO2005003101 A3 WO 2005003101A3 GB 2004002849 W GB2004002849 W GB 2004002849W WO 2005003101 A3 WO2005003101 A3 WO 2005003101A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
rho kinase
pyrazine
kinase inhibitors
pyridine derivatives
Prior art date
Application number
PCT/GB2004/002849
Other languages
French (fr)
Other versions
WO2005003101A2 (en
Inventor
Veronique Birault
John C Harris
Original Assignee
Biofocus Discovery Ltd
Veronique Birault
John C Harris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0315494.5A external-priority patent/GB0315494D0/en
Application filed by Biofocus Discovery Ltd, Veronique Birault, John C Harris filed Critical Biofocus Discovery Ltd
Priority to EP04743195A priority Critical patent/EP1644365A2/en
Priority to US10/561,914 priority patent/US20090163515A1/en
Priority to CA002530389A priority patent/CA2530389A1/en
Priority to JP2006518333A priority patent/JP2007516196A/en
Publication of WO2005003101A2 publication Critical patent/WO2005003101A2/en
Publication of WO2005003101A3 publication Critical patent/WO2005003101A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention relates to a compound and a group of compounds of formula (I) and (II) with the definitions of R1 -R6 according to claim 1 which are inhibitors of Rho kinase (ROK, ROCK). In addition, the invention relates to methods of treatment and use of the compounds in the manufacture of a medicament for application to a number of therapeutic indications including cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, glaucoma and AIDS. The compounds can be used in screening programmes against protein kinases. The invention also provides methods for making compounds and libraries that include these compounds.
PCT/GB2004/002849 2003-07-02 2004-07-01 Pyrazine and pyridine derivatives as rho kinase inhibitors WO2005003101A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04743195A EP1644365A2 (en) 2003-07-02 2004-07-01 Pyrazine and pyridine derivatives as rho kinase inhibitors
US10/561,914 US20090163515A1 (en) 2003-07-02 2004-07-01 Compounds Which Bind to the Active Site of Protein Kinase Enzymes
CA002530389A CA2530389A1 (en) 2003-07-02 2004-07-01 Pyrazine and pyridine derivatives as rho kinase inhibitors
JP2006518333A JP2007516196A (en) 2003-07-02 2004-07-01 Pyrazine and pyralidine derivatives as Rho kinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0315494.5 2003-07-02
GBGB0315494.5A GB0315494D0 (en) 2003-07-02 2003-07-02 Compounds which bind to the active site of protein kinase enzymes
GB0328497.3 2003-12-09
GB0328497A GB2403721A (en) 2003-07-02 2003-12-09 Compounds which bind to the active site of protein kinase enzymes

Publications (2)

Publication Number Publication Date
WO2005003101A2 WO2005003101A2 (en) 2005-01-13
WO2005003101A3 true WO2005003101A3 (en) 2005-03-24

Family

ID=33566546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002849 WO2005003101A2 (en) 2003-07-02 2004-07-01 Pyrazine and pyridine derivatives as rho kinase inhibitors

Country Status (4)

Country Link
EP (1) EP1644365A2 (en)
JP (1) JP2007516196A (en)
CA (1) CA2530389A1 (en)
WO (1) WO2005003101A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7013213B2 (en) 2017-05-26 2022-01-31 日本化薬株式会社 Pyrazine compound

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360152T3 (en) 2003-09-22 2011-06-01 Euro-Celtique S.A. PHENYL-CARBOXAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN.
DK1689715T3 (en) * 2003-12-03 2011-05-23 Ym Biosciences Australia Pty tubulin inhibitors
NZ547696A (en) 2003-12-23 2009-12-24 Astex Therapeutics Ltd Pyrazole derivatives as protein kinase modulators
US20090196912A1 (en) * 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
CA2585490A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
WO2007076360A1 (en) * 2005-12-22 2007-07-05 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
GB0500226D0 (en) * 2005-01-07 2005-02-16 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
EP1848435B1 (en) 2005-01-25 2016-01-20 Synta Pharmaceuticals Corp. Compounds against inflammations and immune-related uses
JP2008546751A (en) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド Pharmaceutical composition
EP1933832A2 (en) 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US20080021026A1 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
KR20220151013A (en) 2007-08-29 2022-11-11 센주 세이야꾸 가부시키가이샤 Agent for promoting corneal endothelial cell adhesion
WO2009107391A1 (en) * 2008-02-27 2009-09-03 武田薬品工業株式会社 Compound having 6-membered aromatic ring
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
MX2010013952A (en) 2008-06-18 2011-02-18 Inspire Pharmaceuticals Inc Process for the preparation of rho-kinase inhibitor compounds.
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US8193363B2 (en) 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
CA2817712C (en) 2010-11-12 2020-03-24 Georgetown University Immortalization of epithelial cells and methods of use
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP3517604A1 (en) 2011-12-06 2019-07-31 Astellas Institute for Regenerative Medicine Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
EP3553169B1 (en) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
CN104837842A (en) * 2012-12-10 2015-08-12 霍夫曼-拉罗奇有限公司 Novel bi-ring phenyl-pyridines/pyrazines for treatment of cancer
WO2014090692A1 (en) * 2012-12-10 2014-06-19 F. Hoffmann-La Roche Ag Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer
JP6548576B2 (en) 2013-07-30 2019-07-24 京都府公立大学法人 Corneal endothelial cell marker
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
JPWO2015064768A1 (en) 2013-10-31 2017-03-09 京都府公立大学法人 Drugs for diseases related to endoplasmic reticulum cell death in corneal endothelium
US11624053B2 (en) 2013-11-27 2023-04-11 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
JP2017522016A (en) 2014-06-27 2017-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cultured mammalian limbal stem cells, production method thereof and use thereof
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN107636149A (en) 2015-04-03 2018-01-26 普罗帕格尼克斯公司 The vitro proliferation of epithelial cell
US10066201B2 (en) 2015-09-11 2018-09-04 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
WO2017064119A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4218773A1 (en) 2016-02-15 2023-08-02 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof
JP2019019124A (en) * 2017-07-19 2019-02-07 日本化薬株式会社 Pyrazine compound
IT201800003040A1 (en) * 2018-02-26 2019-08-26 Univ Pisa New activators of the SIRT1 enzyme for the treatment of cardiovascular and cardiometabolic diseases
CA3107502A1 (en) 2018-08-20 2020-02-27 Chengkang ZHANG Epithelial cell spheroids
EP3843845A4 (en) 2018-08-29 2022-05-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
US20210207088A1 (en) 2018-08-31 2021-07-08 The Doshisha Composition and method for preserving or culturing ocular cells
EP3862424A4 (en) 2018-10-02 2022-06-29 The Doshisha Method and vessel for preserving corneal endothelial cells
UY38427A (en) 2018-10-26 2020-05-29 Novartis Ag METHODS AND COMPOSITIONS FOR EYE CELL THERAPY
WO2021172554A1 (en) 2020-02-27 2021-09-02 京都府公立大学法人 Functional human corneal endothelial cells and application thereof
CN115667504A (en) 2020-04-27 2023-01-31 诺华股份有限公司 Methods and compositions for ocular cell therapy
EP4334437A1 (en) 2021-05-03 2024-03-13 Astellas Institute for Regenerative Medicine Methods of generating mature corneal endothelial cells
WO2023069949A1 (en) 2021-10-18 2023-04-27 Evia Life Sciences Inc. Compositions and methods of use thereof for treating liver fibrosis
WO2023067394A2 (en) 2021-10-22 2023-04-27 Evia Life Sciences Inc. Methods for making extracellular vesicles, and compositions and methods of use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017995A1 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
WO2002024681A2 (en) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
WO2002094814A1 (en) * 2001-05-08 2002-11-28 Schering Aktiengesellschaft 3,5-diamino-1,2,4-triazoles as kinase inhibitors
WO2003051366A2 (en) * 2001-12-13 2003-06-26 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
WO2003062227A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
WO2003099796A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
WO2004016597A2 (en) * 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
WO2004085409A2 (en) * 2003-03-28 2004-10-07 Biofocus Discovery Ltd Compounds and libraries of pyridines, pyrazines, imidazo[1,2-a]pyrazines and 1h-imidazo[4,5-b]pyrazin-2-ones and first and second medical uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017995A1 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
WO2002024681A2 (en) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
WO2002094814A1 (en) * 2001-05-08 2002-11-28 Schering Aktiengesellschaft 3,5-diamino-1,2,4-triazoles as kinase inhibitors
WO2003051366A2 (en) * 2001-12-13 2003-06-26 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
WO2003062227A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
WO2003099796A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
WO2004016597A2 (en) * 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
WO2004085409A2 (en) * 2003-03-28 2004-10-07 Biofocus Discovery Ltd Compounds and libraries of pyridines, pyrazines, imidazo[1,2-a]pyrazines and 1h-imidazo[4,5-b]pyrazin-2-ones and first and second medical uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BOWMAN, R. E. ET AL: "Preparation and cyclization of 3-aza-1,5-diketones", XP002308867, retrieved from STN Database accession no. 1973:29148 *
JEANJOT P ET AL: "N-(alkyl)-2-amino-1,4-pyrazine derivatives: Synthesis and antioxidative properties of 3- and 3,5-p-hydroxyphenyl-substituted compounds", SYNTHESIS, GEORG THIEME VERLAG. STUTTGART, DE, no. 4, 7 March 2003 (2003-03-07), pages 513 - 522, XP002287849, ISSN: 0039-7881 *
JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999) , (22), 2878-82 CODEN: JCPRB4; ISSN: 0300-922X, 1972 *
LUMMA W C ET AL: "Piperazinylpyrazines with central serotoninmimetic activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 21, no. 6, 1978, pages 536 - 542, XP002287850, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7013213B2 (en) 2017-05-26 2022-01-31 日本化薬株式会社 Pyrazine compound

Also Published As

Publication number Publication date
JP2007516196A (en) 2007-06-21
EP1644365A2 (en) 2006-04-12
WO2005003101A2 (en) 2005-01-13
CA2530389A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
WO2005003101A3 (en) Pyrazine and pyridine derivatives as rho kinase inhibitors
WO2002076976A3 (en) Rho-kinase inhibitors
WO2004029045A3 (en) Process for preparing quinazoline rho-kinase inhibitors and intermediates thereof
MY142915A (en) Rho-kinase inhibitors
MX2007014619A (en) Pyrrolopyridines useful as inhibitors of protein kinase.
WO2007076092A3 (en) Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases
WO2004096234A3 (en) Kinase inhibitor phosphonate conjugates
ATE381557T1 (en) RHO KINASE INHIBITORS
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
WO2004058769A3 (en) Triazolopyridazines as protein kinases inhibitors
WO2005037198A3 (en) Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
UA84930C2 (en) Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MXPA05012025A (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors.
WO2004009549A3 (en) Piperidines useful for the treatment of central nervous system disorders
WO2008036540A3 (en) Rho kinase inhibitors
WO2002098865A3 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
ZA200702645B (en) Diaminotriazole compounds useful as protein kinase inhibitors
MXPA05012026A (en) Azaindole compounds as kinase inhibitors.
WO2002064083A3 (en) Synthesis of 3-amino-thalidomide and its enantiomers
MX2009005011A (en) Imidazopyrazines as protein kinase inhibitors.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004743195

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2530389

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006518333

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004743195

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10561914

Country of ref document: US